Antiplatelet
Deep-Dive: Argatroban Plus DAPT in Branch Atherosclerosis Disease — Halves END
Argatroban+DAPT vs DAPT alone in high-risk branch atherosclerosis disease (n=100): END 20.4% vs 47.1% (P=0.006), mRS 0–1 87.8% vs 68.6% (P=0.025), no excess bleeding.